Moolec Science Sa · NASDAQ:MLEC
Moolec Science Sa — SPAC Merger (October 2022)
45 slides from Moolec Science Sa's SPAC merger presentation, Oct 28, 2022
Slide 1: Investor Presentation October 2022
Investor Presentation October 2022
Slide 2: Disclaimer and Forward-Looking Statements
SCIENCE IN ALTERNATIVE .02 This presentation was prepared for informational purposes only by Moolec Science Limited, (“Moolec”) and LightJump Acquisition Corporation (“LightJump”) and is intended to be provided only to accredited institutional investors who are considering an investment in Moolec. T
Slide 3: Planting the Future of Food
ALTERNATIVE .0 3 Planting the Future of Food Moolec is a science - based food ingredient company focused on the use of Molecular Farming technology. Our purpose is to upgrade taste, nutrition, and afford ability of alternative protein products while building a more sustainable and equitable food sys
Slide 4: Moolec's innovation starts at the beginning of the food value chain
Moolec's innovation starts at the beginning of the food value chain. Business Model Contracted Growers & Downstream Partnership or Licensing Model Modified Seeds Moolec’s IP Retail / Food Services Consumers Food Producers & CPG Companies Ingredient Companies B2B Plant - based Animal Protein Ingredien
Slide 5: Moolec's Operations hubs
We operate through hubs in established locations where cutting - edge R&D and science services are provided, and optimal natural conditions for crop development are present . Crop Science & Cultivation ALTERNATIVE .0 5 WISCONSIN CROP INNOVATION CENTER Back Office & Cultivation Food Science Hub Molec
Slide 6: World Class Management Team
World Class Management Team ALTERNATIVE .0 6 Top Ph.Ds and recognized professionals that come from all over the world conform Moolec’s team in line with our global ambitions and targeted footprint. Martín Taraciuk, M.Fin Investors Relations 8+ years in investor relations roles for public listed comp
Slide 7: Pro-Forma Ownership
Pro - Forma Ownership 1 (NASDAQ:BIOX) 5% 39% 39% Company LLC The Biotech 4 SCIENCE IN ALTERNATIVE PROTEINS .0 7 1 Assumes no LJAQ Public Stockholders exercise redemption rights i n connection with the business combination ; actual redemptions may differ . For a complete description of all the assump
Slide 8: Pioneering the future of alternative protein production with Molecular Farming
1 Moolec's internal analysis based on publicly disclosed information for the industry, primarily the GFI State of Industry Report 2021 (March 2022) 2 This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company 3 Both granted and pending 4 https: / ourworldindata.org/foo
Slide 9: Spin-off from Bioceres Group
ALTERNATIVE .0 9 Bioceres transferred full ownership of patents and 10+ years experience in Molecular Farming technology to form a standalone, food - science - focused company. A spin - off from Bioceres Group Science applied to alternative proteins (Bioceres S.A. Private entity) Scientific Team + I
Slide 10: Moolec's Pathway to Public Listing
ALTERNATIVE . 1 0 2008 2014 2018 2020 2022 Lab Pilot plant SPC Patents Approvals Industrial Scale Company Building Expected Listing From Sa ffl ower to Soy Spin - o ff (UK Entity) 2021 GLA IP Incorporation 10 years building our technology Technology scale - up (NASDAQ:BIOX) (Bioceres S.A. - Private
Slide 11: Backers & Partners
Moolec's shareholders and strategic partners bring key experience, advisory, scientific know - how, and access to facilities to strengthen the business. ALTERNATIVE .1 1 Backers & Partners ; Global presence ; Commitment in developing long - term, innovative, and sustainable projects . ; Business : o
Slide 12: Why Moolec?
Why Moolec ? 0 1 Categorycreators: science - based & high - value added company pioneer of the 4th technological pillar within the alternative protein industry. 0 Unmatch e 3 d value proposition: advantages include lower cost, higher scale, and better organoleptic experience. 0 Long - sta n 6 ding b
Slide 13: The Industry
The Industry
Slide 14: Weakness of global food supply chain is on the spotlight
SCIENCE IN ALTERNATIVE PROTEINS .1 4 Weakness of global food supply chain is on the spotlight due to present context. Economic 1 Enviro n mental 3 Nutrition 5 Pests & Diseases 7 ; War in Ukraine is amplifying global food crisis 2 . ; World Bank expects upward pressure on commodity and agriculture pr
Slide 15: Food System Overview
SCIENCE IN ALTERNATIVE PROTEINS . 1 5 USA & Argentina among the top 3 countries of soybean producers worldwide Greenhouse Gas Emissions (GHG) from average food consumption Highest population growth expected in developing countries with low GDP per capita Plants Animals People Soybean: most consumed
Slide 16: Total Addressable Market
T o t a l Addressable Market 1 Alternative Protein Traditional Meat Consumption Share (%) Alternative Meat Consumption Share (%) Massive opportunity to play in a double - digit growing industry (17% CAGR). SCIENCE IN ALTERNATIVE PROTEINS .1 6 1 Sources: ; Moolec’s internal analysis based on publicly
Slide 17: Alternative Proteins Industry
Genuine animal meat produced by cultivating animal cells directly. Made of the same cell types arranged in the same or similar structure as animal tissues, thus replicating sensory and nutritional profiles of conventional meat. Plant - Based 1 Products made from plants that are alternatives to animal
Slide 18: Taste and texture, nutritional values, scalability and low costs
Taste and texture Nutritional values Scalability and low costs SCIENCE IN ALTERNATIVE PROTEINS .1 8
Slide 19: The solution: Moolec as a Category Creator
Molecular Farming has the potential to overcome the main obstacles faced by other technologies in the alternative protein landscape. The solution: Moolec as a Category Creator 1 Taste and texture Plant - based Plants Science Plants + Science Fermentation Cultured meat Molecular Farming Nutritional v
Slide 20: Molecular Farming Ecosystem
Molecular Farming Ecosystem 1 Dairy Growth Factors 12 Meat Dairy proteins in discarded fruit Meat proteins in s oybean s & p ea The industry is growing with stronger recognition of the advantages of Molecular Farming. Moolec is the only player focused on growing meat proteins in both soy and pea see
Slide 21: The Technology
The Technology
Slide 22: Animal Proteins in Plants
SCIENCE IN ALTERNATIVE .2 2 Moolec introduces real animal genes in the plant's genome to give real taste and nutrition to food. Animal Proteins in Plants Traditional Molecular Farming Seeds Food Crops Feed Livestock Crops Seeds Food - G a ni Cruelty - Free PROTEINS
Slide 23: Molecular Farming: a cost-effective way to produce alternative proteins
SCIENCE IN ALTERNATIVE .2 3 Molecular Farming: a cost - effective way PROTEINS to produce alternative proteins 1 1 Moolec's internal analysis based on publicly disclosed information for the industry and management estimates
Slide 24: Molecular Farming is more friendly to the environment
8X less 2 Molecular Farming is more friendly to the environment when compared to traditional protein productive systems. SCIENCE IN ALTERNATIVE PROTEINS .2 4 Moolec vs. Animal - based Production System 1 https://ourworldindata.org/agricultural - land - by - global - diets 2 https://waterfootprint.or
Slide 25: Molecular Farming in a Nutshell
Selection Transformation Production Development Scale - Up SCIENCE IN ALTERNATIVE .2 5 Molecular Farming in a Nutshell .01 Real DNA (protein of interest) is isolated .04 .05 Plant - based Animal Protein Ingredients .08 .07 Gene is inserted into expression vector .02 .03 Vector is inserted into plant
Slide 26: Proof of Concept: Why Chymosin?
22 SCIENCE IN ALTERNATIVE . 26 Proof of Concept: Why Chymosin? Chymosin is a validation molecule in biotechnology by being the first protein for food been approved by the FDA with precision fermentation 1 This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company “Grou
Slide 27: Transferrable & scalable technology
T r ans f er r abl e & scalable technology Soy Plant - Based Chymosin Safflower Protein content 20% 40% Scalability 120K has 50M has Yield 1 ton/ha 5 ton/ha Market 350M Chymosin 1 . 5B Meat Replacement Soy proteins + Meat Proteins ALTERNATIVE .2 7 Based on our Proof of Concept we were able to extend
Slide 28: Fermentation: Our Validation Platform
Fermentation: Our Validation Platform ALTERNATIVE .2 8 Precision fermentation complements Molecular Farming technology as validation stage and faster go - to - market pathway. Fast application testing Quick regulatory footprint IP discovery Partnerships and commercial opportunities Product developme
Slide 29: Pipeline & Products
Pipeline & Products
Slide 30: Pipeline Status
Pipeline Status SCIENCE IN ALTERNATIVE PROTEINS . 30 Dairy ingredient and Nutr itional oil (Chymosin & GLA) Meat Replacement (POORK+ & BEEF+) PROGRAM HOST S afflo wer Yeast Soybean Pea PROJECT PHASE 1 PLANED COMMERCIAL LAUNCH 2025 2025 2025 2025 2026 2027 202 9 202 9 TBD 2028 350M 3 1 . 5B 4 1 . 5B
Slide 31: Current industry challenges
SCIENCE IN ALTERNATIVE PROTEINS .31 Current industry challenges Not clean label. 20+ different components Not fully natural. Synthetic and chemical additives Not the same nutritional values to animal - based Plant Proteins Sunflower & Coconut Oils Water Flavouring & Appearance Binding & Texturizing 5
Slide 32: Moolec's Substitute Process by Cost
SCIENCE IN ALTERNATIVE PROTEINS . 32 PHASE 1 PHASE 2 PHASE 3 PHASE 4 50% Flavouring & Appearance 15% Binding & Texturizing 14% Plant Proteins 20% Sunflower & Coconut Oils + + + 99% of the cost = 50% Fla vouring & Appear ance 15% Binding & Texturizing 14% Plant Proteins 20% Sunflower & Coconut Oils 1%
Slide 33: Products: POORK+, plant-based chymosin, GLA
1 Applies to plant - based Chymosin, POORK+ and BEEF+ products. GLA is a plant - based nutritional oil 2 The FDA has approved the GLA - containing safflower seed oil as a new ingredient in dietary supplements, nutritional beverages, and medicinal foods for humans. The FDA has also approved the use o
Slide 34: Today most consumers accept GMO food
T od a y most consumers accept GMO Food 98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout confirmed that GMO is no longer a material issue in the US consumer's minds 1,2 . Transparency and the cause's purpose are key Discussion gravitates around science, hunger
Slide 35: Regulatory Pathway
ALTERNATIVE . 35 Regulatory Pathway Moolec is subject to the laws and regulations governing biotechnology and food companies in the jurisdictions in which we operate . Regulation of Plant Biotechnology Products Regulation of Food and Ingredient Products Other Regulatory Requirements Subject regulati
Slide 36: Strong and growing IP strategy
ALTERNATIVE . 36 Moolec stands on a strong and growing IP strategy with great understanding of the biotech landscape offering a competitive advantage on its execution. Patent Portfolio 1 7 Patents Canada Italy GLA France UK 3 P a t e nts Argentina Spain New ealand China Brasil Germany France UK Hong
Slide 37: Latest Milestones
Latest Milestones ALTERNATIVE . 37 Pea Ongoing transformation and regeneration stage Chymosin SPC Planted in Córdoba, Argentina June 2022 Soybean T1 seed harvested. Next phase for achieving T2 & T3 seeds started August 2022 GLA Planted in Idaho Falls, USA, harveste d October 2022 SPC x GLA Back Cros
Slide 38: Environmental, social and governance (ESG)
Environmental, social and governance (ESG)
Slide 39: Moolec addresses directly 10 of the 17 SDGs
We use SDGs and 2030 Agenda as guidelines to strategically align our business in the search of the building of a more equitable, resilent and sustainable food system 1,2 . From ending poverty, hunger to responding to climate change, food and agriculture lie at the very heart of the 2030 Agenda for S
Slide 40: Environmental & Social Impact
SCIENCE IN ALTERNATIVE PROTEINS Moolec’s technology is much more friendly to the environment and promotes an inclusive global value chain, bringing farmers back to the equation. 1 Sources: ; https:/ /ww w .studyfinds.org/taste - plant - based - diet/ ; https:/ /ww w .foodnavigator - asia.com/Article/
Slide 41: Using all parts of the plants: circular strategy
Focus ed on using all parts of the plants 1 SCIENCE IN ALTERNATIVE PROTEINS . 41 Oil s as high - valued by - product Starches for feed and/ or bioplastics Leaves for carbon sequestration and soil composting Fiber as source for renewable energy We create sustainable products and by - products followi
Slide 42: Appendix
Appendix
Slide 43: Transaction Overview – Capitalization, Sources, and Uses
SCIENCE IN ALTERNATIVE PROTEINS .4 3 T r ansactio n Overview – Capitalization, Sources, and Uses Total Sources $28 M $325 M $0 M $35 3 M Transaction Sources and Uses Sources SPAC cash in trust 1 Moolec Shares (rollover equity) Backstop 8 Total Uses $16 M $325 M $12 M $35 3 M $14 M $325 M $0 M $339 M
Slide 44: Latest Detail Pro-Forma Ownership
SCIENCE IN ALTERNATIVE PROTEINS Latest Detail Pro - Forma Ownership BG Farming Technologies Ltd. Union Group Ventures Ltd. Bioceres Crop Solutions Corp. SAFE Holders Initial Stockholders 3 LightJump Public Stockholders Key Team Members Participation UG Holdings LLC Total 0% 1 15,275,000 15,275,000 1
Slide 45: Follow us! www.moolecscience.com
d Follow us! www.moolecscience.com scienc or the good of the planet